Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment?. Issue 3 (20th January 2020)

• Record Type: Journal Article
• Authors: Xiang, Liyuan; Ding, Xiao; Li, Qianqian; Wu, Xia; Dai, Min; Long, Chuyan; He, Zhi; Cui, Bota; Zhang, Faming
• Is Part Of: Microbial biotechnology. Volume 13:Issue 3(2020:May)
• Page Start: 760
• Page End: 769
• Publication Date: 2020-01-20
• Subjects: Microbial biotechnology -- Periodicals; Biotechnology; Microbiology; 660.62
• DOI: 10.1111/1751-7915.13536
• Languages: English
• ISSNs: 1751-7915

Abstract

Summary: The efficacy of faecal microbiota transplantation (FMT) in Crohn's disease (CD) remains unclear due to lack of data. This study aimed to assess the value of FMT in treating CD‐related clinical targets. The use of FMT for CD as a registered trial (NCT01793831) was performed between October 2012 and December 2017. Seven therapeutic targets included abdominal pain, diarrhoea, hematochezia, fever, steroid‐dependence, enterocutaneous fistula and active perianal fistula. Each target was recorded as 1 (yes) or 0 (no) during the long‐term follow‐up for each patient. The primary outcome was the rate of improvement in each therapeutic target. Overall, 174 patients completed the follow‐up. The median follow‐up duration was 43 (interquartile range, 28–59) months. The median score of the total targets was 2 (range, 1–4) before FMT, and it decreased significantly at 1, 3, 6, 12, 24 and 36 months after FMT ( P < 0.001 respectively). At 1 month after FMT, 72.7% (101/139), 61.6% (90/146), 76% (19/25) and 70.6% (12/17) of patients achieved improvement in abdominal pain, diarrhoea, hematochezia and fever respectively. Furthermore, 50% (10/20) of steroid‐dependent patients achieved steroid‐free remission after FMT. The present findings indicate that it is important to understand the efficacy of FMT in CD as a targeted therapy, especially for abdominal pain, hematochezia, fever and diarrhoea. Abstract : This study aimed to assess the value of FMT in treating CD‐related clinical targets. The present findings indicate that it is important to understand the efficacy of FMT in CD as a targeted therapy, especially for abdominal pain, hematochezia, fever, and diarrhea.